New hope for advanced thyroid cancer: personalized drug cocktails tested
NCT ID NCT07485569
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving advanced thyroid cancer patients a personalized mix of already-approved drugs, chosen based on their tumor's genetic profile, is feasible and safe. Ten patients with no other treatment options will receive individualized drug combinations. The goal is to see if this approach can control tumor growth or stop it from worsening.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- approved drugs (personalized combination)
- What this could lead to
- If successful, this could show that personalized drug repurposing is feasible and safe, potentially offering a new treatment path for advanced thyroid cancer patients.
- What could go wrong
- This is a very early, small pilot trial with only 10 participants. It may not show clear benefit, and the personalized approach may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a sharp beam of radiation tame spreading thyroid cancer?
- Two-Drug combo takes aim at deadly thyroid cancer
- Immunotherapy added to standard drugs may fight aggressive thyroid cancer
- Could drug holidays improve thyroid cancer treatment?
- Radiation safety study aims to personalize thyroid cancer treatment
- Which neck surgery hurts least? new study aims to find out